Anondita Medicare Limited is a well-established manufacturer of male condoms under the flagship brand COBRA. The company has an impressive installed capacity of 562 million condoms annually, catering to both domestic and international markets with a wide range of flavoured and regular variants.

The company has brought its Book Built IPO of ₹69.50 crores, entirely a Fresh Issue of 47.93 lakh shares, which attracted overwhelming investor participation. The IPO was open for subscription from 22 August 2025 to 26 August 2025, and saw extraordinary demand across all categories, being subscribed 114.77 times in total.

IPO Price Band, Lot Size and Market Capitalisation

The IPO price band was set between ₹137 and ₹145 per share, with a lot size of 1,000 shares. Retail investors were required to apply for a minimum of 2 lots (2,000 shares), translating to an investment of ₹2,90,000.

At the upper price band of ₹145, the IPO pegs the market capitalisation of Anondita Medicare at approximately ₹262.26 crores, placing it strongly among peers in the NSE SME segment.

Grey Market Premium (GMP) – Indication of Listing Gains

As per the latest reports, the Grey Market Premium (GMP) of Anondita Medicare IPO was around ₹25, which translates to an expected listing price of ₹170, about 17.24% higher than the issue price of ₹145.

While GMP is an unofficial indicator and not regulated, it reflects market sentiment and investor demand. However, experts always advise that investors must not rely solely on GMP for decision-making.

Subscription Status – Record Demand from Investors

The subscription demand for Anondita Medicare IPO was phenomenal, highlighting the strong investor confidence in the company’s financials and growth potential.

• Qualified Institutional Buyers (QIBs): Subscribed heavily, reflecting faith of institutional investors.

• Non-Institutional Investors (NIIs): Oversubscribed manifold due to HNI participation.

• Retail Investors: Strong subscription, showing high interest from small investors.

By the end of the final day (26 August 2025), the IPO was subscribed 114.77 times, making it one of the most successful SME IPOs of the year.

Anchor Investors Participation

On 21 August 2025, ahead of the IPO opening, Anchor Investors infused ₹19.60 crores at the upper price band of ₹145 per share. A total of 13,52,000 equity shares were allocated to anchor investors, ensuring a strong base for the issue.

This step not only provided confidence to retail and HNI investors but also highlighted the institutional backing for the IPO.

Allotment and Listing Details

The IPO allotment date is set for 28 August 2025 (Thursday). Investors can check their allotment status online by:

1. Visiting the registrar website (Maashitla Securities Pvt. Ltd.).

2. Selecting Anondita Medicare IPO from the list of IPOs.

3. Entering their PAN, DP Client ID, or Application Number.

4. Submitting details to view allotment status.

The shares will be credited to successful applicants by 30 August 2025, and the listing is tentatively scheduled for 1 September 2025 on NSE SME.

Objectives of the IPO

Anondita Medicare plans to utilise the net proceeds from the IPO in the following manner:

1. ₹600 lakh for capital expenditure on new machinery and equipment.

2. ₹3,500 lakh for working capital requirements, supporting expansion in domestic and international operations.

3. Remaining funds to be used for general corporate purposes and potential acquisitions.

Business Strengths and Growth Potential

• Strong Brand Recall: The flagship brand COBRA has high recognition in the Indian condom market.

• Large Production Capacity: With 562 million units annual capacity, the company can meet increasing demand.

• Growing Market Opportunity: Rising awareness about sexual health and contraceptives offers growth opportunities.

• Diverse Flavours & Variants: Wide product portfolio caters to both domestic and export markets.

• Experienced Management: Decades of experience in the healthcare and wellness industry.

Risks and Challenges Investors Must Note

• Dependence on Raw Materials: Price fluctuations can impact margins.

• Competition: Both organised brands and unorganised players pose challenges.

• Regulatory Risks: Being in healthcare, the company is subject to regulatory oversight.

• SME Listing Risks: Liquidity in SME shares can be lower compared to mainboard IPOs.

Conclusion

The Anondita Medicare IPO has received massive subscription of 114.77 times, indicating strong investor confidence. With a GMP of ₹25 suggesting potential listing gains, along with solid anchor backing and strong fundamentals, the IPO has created buzz in the market.

However, investors must weigh the risks of SME IPOs and invest with a long-term perspective. The upcoming listing on 1 September 2025 will be closely watched by the market to see if it matches or exceeds the high expectations set during the subscription phase.

The Upcoming IPOs in this week and coming weeks are Amanta Healthcare, Rachit Paints, Abril Paper Tech, Sneha Organics, Sugs Lloyd, .

The Current active IPO are Anlon Healthcare, NIS Management, Sattva Engineering Construction, Globtier Infotech, Current Infraprojects, Vikran Engineering, Shivashrit Foods, Anondita Medicare, Classic Electrodes (India).

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.